We welcome our two new associates: Richard Johnson and Fredrik Gunnarsson. Richard is a Mechanical Engineer and Fredrik is an Analytical Chemist.
Iconovo was a Bronze sponsor of DDL in Edinburgh. The sponsorship was in cooperation with EU financed SSGG project.
Dr Mikael Arinder is Iconovo’s new Vice President Operations. Mikael has a PhD. in organic chemistry and has long experience from the pharmaceutical industry and particularly from the respiratory area. Mikael was with AstraZeneca for 14 years and had many senior roles. He now joins us from McNeal where he was Associate Director of Analytical Development. Mikael will be responsible for Iconovo’s customer projects.
Iconovo has signed an agreement for a licensing deal and a product development project with Amneal Pharmaceuticals that produce and market generic drug products. The agreement involves an adaptation of Iconovo’s unique inhaler, ICOres™ as well as a development of a powder formulation to treat asthma and COPD. Iconovo will receive an up-front payment and milestone payments in the mid-single digit Euro millions range during development through regulatory approvals and royalties after commercial launch.
Iconovo has received a 350 000 USD grant from Sweden’s innovation agency Vinnova. The development project includes optimization of ICOone and adaptation for high-volume low-cost commercial manufacturing. ICOone is primary intended for inhaled vaccines but is also suitable for biomolecules and high cost drugs.
Iconovo has signed a development agreement with Copenhagen University. Iconovo’s unit-dose inhaler ICOone will be used in two PhD projects investigating novel drug formulations at Faculty of Health and Medical Sciences. ICOone is the perfect test device when developing either traditional drug formulations or novel engineered drug formulations.
Iconovo won the Lund University Innovation Award. The winning project was “ICOone for inhaled vaccines”. Vaccines are currently administered as injections, which in addition to the associated discomfort also presents a variety of other challenges. One major problem with needles is that they are dangerous to use and can spread infections if not properly handled after use. Another concern is that vaccines for injection must be refrigerated, which is costly and large quantities of vaccine may need to be discarded as a result. Iconovo’s technology solves such problems since the shelf life of inhaled dry powder at room temperature is several months and the inhaler is completely harmless during and after use.
Iconovo is in the finals to win the Lund University Innovation Award. ICOone for inhaled vaccine was presented to the jury and judged on the level of innovation and commercial potential. Iconovo was selected top three with a chance to win the innovation award. First prize is 1 500 00 SEK and the two second prizes are 500 00 SEK. The winner will be announced at the 6th of November at a ceremony in Lund. The award is sponsored by PWC.